Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Ye, Zhi Kang ^a,b   Tang, Hui Lin ^a   Zhai, Suo Di ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VANCOMYCIN;

ARTICLE; ASIAN; BACTEREMIA; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; GRAM POSITIVE INFECTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LENGTH OF STAY; META ANALYSIS; MORTALITY; NEPHROTOXICITY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DATABASES, BIBLIOGRAPHIC; DRUG MONITORING; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LENGTH OF STAY; MALE; NEPHROTIC SYNDROME; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84885809400     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077169     Document Type: Article

References (46)

1. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N, (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67: 17-24.
2. Moellering RC Jr, (2006) Vancomycin: a 50-year reassessment. Clin Infect Dis 42 Suppl 1: S3-4.
3. Levine DP, (2006) Vancomycin: a history. Clin Infect Dis 42 Suppl 1: S5-12.
4. Rybak MJ, (2006) The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42 Suppl 1: S35-39.
5. Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE, (2003) Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 23: 643-650.
6. Cantu TG, Yamanaka-Yuen NA, Lietman PS, (1994) Serum vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 18: 533-543.
7. Karachalios GN, Tziviskou EM, (1998) Vancomycin: Is it necessary the therapeutic drug monitoring? Epitheorese Klinikes Farmakologias kai Farmakokinetikes 16: 110-119.
8. Pryka RD, (1994) Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother 28: 1397-1399.
9. Moellering RC Jr, (1994) Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 18: 544-546.
10. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, et al. (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66: 82-98.
11. Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, et al. (2013) Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother.
12. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, et al. (2004) Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38: 521-528.
13. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, et al. (2008) Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 52: 3315-3320.
14. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, et al. (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42: 2398-2402.
15. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A, (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166: 2138-2144.
16. De Cock P, Haegeman E, Goerlandt N, Vanhaesebrouck P, Stove V, et al. (2010) Focused Conference Group: P13- Maximising benefits and minimizing harms from drugs vancomycin dosing and monitoring in children: Compliance with guidelines in a belgian teaching hospital. Basic Clin Pharmacol 107: 250-251.
17. Li J, Udy AA, Kirkpatrick CM, Lipman J, Roberts JA, (2012) Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. Int J Antimicrob Ag 39: 69-72.
18. Khotaei GT, Jam S, SeyedAlinaghi S, Motamed F, Nejat F, et al. (2010) Monitoring of serum vancomycin concentrations in pediatric patients with normal renal function. Acta Medica Iranica 48: 91-94.
19. Mariani-Kurkdjian P, Nebbad H, Aujard Y, Bingen E, (2008) [Monitoring serum vancomycin concentrations in the treatment of Staphylococcus infections in children]. Arch Pediatr 15: 1625-1629.
20. Commandeur D, Giacardi C, Danguy Des Deserts M, Huynh S, Buguet-Brown ML, et al. (2011) [Monitoring vancomycin in an intensive care unit: A retrospective survey on 66 patients]. Med Mal Infect 41: 410-414.
21. Reis AGAC, Grisi SJFE, (1996) Monitorization of blood levels of vancomycin in children with multi-resistant bacterial infections. Jornal de Pediatria 72: 225-229.
22. Pea F, Poz D, Baraldo M, Furlanut M, (2000) Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function- Multiple daily doses may be preferable. Clin Drug Invest 19: 213-218.
23. Miles MV, Li L, Lakkis H, Youngblood J, McGinnis P, (1997) Special considerations for monitoring vancomycin concentrations in pediatric patients. Ther Drug Monit 19: 265-270.
24. Hochart C, Berthon C, Corm S, Gay J, Cliquennois M, et al. (2011) Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia. Med Mal Infect 41: 652-656.
25. Marengo LL, Del Fiol Fde S, Oliveira Sde J, Nakagawa C, Croco EL, et al. (2010) Vancomycin: the need to suit serum concentrations in hemodialysis patients. Braz J Infect Dis 14: 203-208.
26. Eiland LS, English TM, Eiland EH, (2011) Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother 45: 582-589.
27. Wells GS, Shea B, O'Connell D, Peterson J, Welch V, et al. (2005) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (20 Apirl 2013, data last accessed).
28. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
29. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
30. Welty TE, Copa AK, (1994) Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 28: 1335-1339.
31. Fernandez de Gatta MD, Calvo MV, Hernandez JM, Caballero D, San Miguel JF, et al. (1996) Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 60: 332-340.
32. Iwamoto T, Kagawa Y, Kojima M, (2003) Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 26: 876-879.
33. Sato S, Saito Y, (2007) Evaluation of the usefulness of vancomycin dosage design based on pharmacokinetics/pharmacodynamics theory. Jpn J Chemother 55: 220-224.
34. Mochizuki T, Sato T, Okinaka K, Kishida N, Fujita T, et al. (2010) Efficacy and safety for vancomycin in uncomplicated catheter-related bloodstream infection by coagulase negative Staphylococcus. Jpn J Chemother 58: 233-238.
35. Huang YZ, Mao MY, Yuan KX, (2011) Clinical application of drug monitoring of vancomycin. Chin J Infec Chemother 11: 295-298.
36. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, et al. (2006) Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130: 947-955.
37. Zhang C, Zhai SD, Liu F, (2009) Necessarity of therapeutic drug monitoring of vancomycin in clinical use: a systematicreview. Chin J Clin Pharmacol 25: 329-333.
38. Long C, Che Amin N, Manan M, (2011) Population pharmacokinetics of vancomycin in hospitalized adult patients at a Malaysian tertiary care hospital. Eur J Pharm Sci 44: 195-196.
39. van de Vijsel LM, Walker SA, Walker SE, Yamashita S, Simor A, et al. (2010) Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis. Can J Hosp Pharm 63: 196-206.
40. Vazquez M, Fagiolino P, Boronat A, Buroni M, Maldonado C, (2008) Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock. Int J Clin Pharmacol Ther 46: 140-145.
41. Lau AH, John E, (1988) Elimination of vancomycin by continuous arteriovenous hemofiltration. Child Nephrol Urol 9: 232-235.
42. Pea F, Porreca L, Baraldo M, Furlanut M, (2000) High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemoth 45: 329-335.
43. Al-Kofide H, Zaghloul I, Al-Naim L, (2010) Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract 16: 245-250.
44. Badran EF, Shamayleh A, Irshaid YM, (2011) Pharmacokinetics of vancomycin in neonates admitted to the neonatology unit at the Jordan University Hospital. Int J Clin Pharmacol Ther 49: 252-257.
45. Golestaneh L, Gofran A, Mokrzycki MH, Chen JL, (2009) Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing. Clin Nephrol 72: 286-291.
46. Dolton M, Xu H, Cheong E, Maitz P, Kennedy P, et al. (2010) Vancomycin pharmacokinetics in patients with severe burn injuries. Burns 36: 469-476.